Abstract
Background Covid-19 has caused significant global mortality. Multiple vaccines have demonstrated efficacy in clinical trials though real-world effectiveness of vaccines against Covid-19 mortality in clinically and demographically diverse populations has not yet been reported.
Methods We used a retrospective cohort assembled from a cross-institution comprehensive data repository. Established patients of the health care system were categorized as not immunized, partially immunized, or fully immunized against SARS-CoV-2 with an mRNA vaccine through April 4, 2021. Outcomes were Covid-19 related hospitalization and death.
Results Of the 91,134 established patients, 70.2% were not immunized, 4.5% were partially immunized and 25.4% were fully immunized. Among the fully immunized 0.7% had a Covid-19 hospitalization, whereas 3.4% among the partially immunized and 2.7% non-immunized individuals were hospitalized with Covid-19. Of the 225 deaths among Covid-19 hospitalizations, 219 (97.3%) were in the not immunized, 5 (2.2%) in the partially immunized, and 1 (0.0041%) in the fully immunized group. mRNA vaccines were 96% (95%CI: 95 — 99) effective at preventing Covid-19 related hospitalization and 98.7% (95%CI: 91.0 — 99.8) effective at preventing Covid-19 related death when participants were fully vaccinated. Partial vaccination was 77% (95%CI: 71 — 82) effective at preventing hospitalization and 64.2% (95%CI: 13.0 — 85.2) effective at preventing death. Vaccine effectiveness at preventing hospitalization was conserved across subgroups of age, race, ethnicity, Area Deprivation Index, and Charlson Comorbidity Index.
Conclusions In a large, diverse cohort in the United States, full immunization with mRNA vaccines was highly effective in the real-world scenario at preventing Covid-19 related hospitalization and death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for the COVID-19 Surveillance and Outcomes Registry (CURATOR) was provided by Houston Methodist and the Houston Methodist Academic Institute. The study was partially funded by the Yale Institute for Global Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Houston Methodist Institutional Review Board (PRO 00025445:1)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
COI: The authors do not report any conflicts of interest,
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.